New pill shows promise for Tough-to-Treat blood cancer
NCT ID NCT06909877
First seen Oct 01, 2025 · Last updated May 19, 2026 · Updated 29 times
Summary
This study tests an experimental oral drug called HH2853 in people with peripheral T-cell lymphoma that has come back or not responded to standard treatments. The drug works by blocking certain proteins that help cancer cells grow. About 100 participants will take the pill daily to see if it can shrink tumors and control the disease. This is an early-phase trial, so the main goals are finding the right dose and checking safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA (R/R PTCL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sichuan Cancer Hospital
RECRUITINGChengdu, Chengdu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.